Cargando…

Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects

SARS-CoV-2 is quickly evolving from wild-type to many variants and spreading around the globe. Since many people have been vaccinated with various types of vaccines, it is crucial to develop a high throughput platform for measuring the antibody responses and surrogate neutralizing activities against...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Tzong-Shiann, Du, Pin-Xian, Su, Wen-Yu, Santos, Harvey M., Lin, Ya-Lan, Chou, Yi-Yu, Keskin, Batuhan Birol, Pau, Chi Ho, Syu, Guan-Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821029/
https://www.ncbi.nlm.nih.gov/pubmed/35168024
http://dx.doi.org/10.1016/j.bios.2022.114067
_version_ 1784646334173675520
author Ho, Tzong-Shiann
Du, Pin-Xian
Su, Wen-Yu
Santos, Harvey M.
Lin, Ya-Lan
Chou, Yi-Yu
Keskin, Batuhan Birol
Pau, Chi Ho
Syu, Guan-Da
author_facet Ho, Tzong-Shiann
Du, Pin-Xian
Su, Wen-Yu
Santos, Harvey M.
Lin, Ya-Lan
Chou, Yi-Yu
Keskin, Batuhan Birol
Pau, Chi Ho
Syu, Guan-Da
author_sort Ho, Tzong-Shiann
collection PubMed
description SARS-CoV-2 is quickly evolving from wild-type to many variants and spreading around the globe. Since many people have been vaccinated with various types of vaccines, it is crucial to develop a high throughput platform for measuring the antibody responses and surrogate neutralizing activities against multiple SARS-CoV-2 variants. To meet this need, the present study developed a SARS-CoV-2 variant (CoVariant) array which consists of the extracellular domain of spike variants, e.g., wild-type, D614G, B.1.1.7, B.1.351, P.1, B.1.617, B.1.617.1, B.1.617.2, and B.1.617.3. A surrogate virus neutralization on the CoVariant array was established to quantify the bindings of antibody and host receptor ACE2 simultaneously to spike variants. By using a chimeric anti-spike antibody, we demonstrated a broad binding spectrum of antibodies while inhibiting the bindings of ACE2 to spike variants. To monitor the humoral immunities after vaccination, we collected serums from unvaccinated, partial, or fully vaccinated individuals with either mRNA-1273 or AZD1222 (ChAdOx1). The results showed partial vaccination increased the surrogate neutralization against all the mutants while full vaccination boosted the most. Although IgG, IgA, and IgM isotypes correlated with surrogate neutralizing activities, they behave differently throughout the vaccination processes. Overall, this study developed CoVariant arrays and assays for profiling the humoral responses which are useful for immune assessment, vaccine research, and drug development.
format Online
Article
Text
id pubmed-8821029
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-88210292022-02-08 Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects Ho, Tzong-Shiann Du, Pin-Xian Su, Wen-Yu Santos, Harvey M. Lin, Ya-Lan Chou, Yi-Yu Keskin, Batuhan Birol Pau, Chi Ho Syu, Guan-Da Biosens Bioelectron Article SARS-CoV-2 is quickly evolving from wild-type to many variants and spreading around the globe. Since many people have been vaccinated with various types of vaccines, it is crucial to develop a high throughput platform for measuring the antibody responses and surrogate neutralizing activities against multiple SARS-CoV-2 variants. To meet this need, the present study developed a SARS-CoV-2 variant (CoVariant) array which consists of the extracellular domain of spike variants, e.g., wild-type, D614G, B.1.1.7, B.1.351, P.1, B.1.617, B.1.617.1, B.1.617.2, and B.1.617.3. A surrogate virus neutralization on the CoVariant array was established to quantify the bindings of antibody and host receptor ACE2 simultaneously to spike variants. By using a chimeric anti-spike antibody, we demonstrated a broad binding spectrum of antibodies while inhibiting the bindings of ACE2 to spike variants. To monitor the humoral immunities after vaccination, we collected serums from unvaccinated, partial, or fully vaccinated individuals with either mRNA-1273 or AZD1222 (ChAdOx1). The results showed partial vaccination increased the surrogate neutralization against all the mutants while full vaccination boosted the most. Although IgG, IgA, and IgM isotypes correlated with surrogate neutralizing activities, they behave differently throughout the vaccination processes. Overall, this study developed CoVariant arrays and assays for profiling the humoral responses which are useful for immune assessment, vaccine research, and drug development. Elsevier B.V. 2022-05-15 2022-02-08 /pmc/articles/PMC8821029/ /pubmed/35168024 http://dx.doi.org/10.1016/j.bios.2022.114067 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ho, Tzong-Shiann
Du, Pin-Xian
Su, Wen-Yu
Santos, Harvey M.
Lin, Ya-Lan
Chou, Yi-Yu
Keskin, Batuhan Birol
Pau, Chi Ho
Syu, Guan-Da
Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
title Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
title_full Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
title_fullStr Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
title_full_unstemmed Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
title_short Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
title_sort development of sars-cov-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821029/
https://www.ncbi.nlm.nih.gov/pubmed/35168024
http://dx.doi.org/10.1016/j.bios.2022.114067
work_keys_str_mv AT hotzongshiann developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects
AT dupinxian developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects
AT suwenyu developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects
AT santosharveym developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects
AT linyalan developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects
AT chouyiyu developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects
AT keskinbatuhanbirol developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects
AT pauchiho developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects
AT syuguanda developmentofsarscov2variantproteinmicroarrayforprofilinghumoralimmunityinvaccinatedsubjects